CAMP4 Therapeutics Prices $75 Million IPO-February 2024-www.financetom.com

CAMP4 Therapeutics Prices $75 Million IPO

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

CAMP4 Therapeutics Prices $75 Million IPO

Oct 11, 2024 5:05 AM

07:33 AM EDT, 10/11/2024 (MT Newswires) -- CAMP4 Therapeutics said late Thursday it priced its initial public offering of about 6.8 million common shares at $11 per share for expected gross proceeds of about $75 million.

Underwriters have been granted a 30-day option to buy up to about 1 million additional shares.

Shares of the biotechnology company are expected to begin trading on Nasdaq this Friday, under the ticker symbol, "CAMP." The IPO is set to close Oct. 15.

Previous page： Charles Schwab's Total Client Assets Rise in January Next page： Indian industries see opportunity in Trump's trade goals

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Charles Schwab's Total Client Assets Rise in January

Feb 14, 2025

09:16 AM EST, 02/14/2025 (MT Newswires) -- Charles Schwab ( SCHW ) said Friday that its total client assets reached $10.33 trillion in January, up 21% year-over-year and 2% sequentially. Core net new assets brought into the company were $30.6 billion in January, up 78% from a year earlier and down 50% from a month earlier, the company said. New...

Indian industries see opportunity in Trump's trade goals

Feb 14, 2025

NEW DELHI (Reuters) - Indian industry and trade experts see an opportunity to expand business with the U.S. after Prime Minister Narendra Modi met President Donald Trump, despite uncertainties over reciprocal tariffs and thanks to steps taken in the past few years. India and the U.S. agreed on Thursday to resume talks to clinch a trade deal later this year,...

Moderna Posts Wider-Than-Expected Quarterly Loss; Revenue Declines Annually

Feb 14, 2025

09:18 AM EST, 02/14/2025 (MT Newswires) -- Moderna's ( MRNA ) fourth-quarter loss came in higher than Wall Street's expectations as its sales fell amid the impact of an early launch of the drugmaker's updated COVID-19 vaccine in the US. The company posted a net loss of $2.91 a share for the December quarter, compared with earnings of $0.55 the...

EU open to tariff talks, but firm on own laws, says senior legislator

Feb 14, 2025

BRUSSELS (Reuters) - The European Union can negotiate on reciprocal tariffs with the United States but will not give up its right to regulate in areas such as taxation and digital platforms, the chair of the European Parliament's trade committee said on Friday. U.S. President Donald Trump has tasked his economics team with devising plans for reciprocal tariffs on every...